ESC 365 - New horizons for the statin intolerant patients: current and future therapeutic options.

Open Access

New horizons for the statin intolerant patients: current and future therapeutic options.

Session: Cardiovascular risk reduction and lipid management: state of the science

Topic: Metabolism and metabolic syndromes

Speaker: Doctor L. Cho (Cleveland, US)

Sponsored by Cleveland Clinic

Event: ESC Congress 2016

Congress Presentation

About the speaker

Doctor Leslie Cho

Cleveland Clinic, Cleveland (United States of America)

15 presentations

1 follower

3 more presentations in this session

Unmet medical needs with current agents and residual CV risk: rationale for developing new agents.

Speaker: Professor S. Nissen (Cleveland, US)

Prospects for clinical benefit with CETP inhibition in light of current and future trials.

Speaker: Professor A. Lincoff (Cleveland, US)

The science of HDL and reverse cholesterol transport – Are we still hopeful?

Speaker: Professor J. Kastelein (Amsterdam, NL)

Access the full session

Cardiovascular risk reduction and lipid management: state of the science

Speakers: Doctor L. Cho, Professor S. Nissen, Professor A. Lincoff, Professor J. Kastelein

About the event

ESC Congress 2016

27 August - 31 August 2016

Sessions Presentations

Congress

ESC 365 is supported by